YMDD and FLLAQ Mutations in Chronic Hepatitis B Patients

Authors

  • Moradi, A, Golestan University of Medical Sciences, Gorgan, Iran
  • Nezamzade, R, Islamic Azad University, Damghan Branch, Iran
  • Rezanezhadi, M, Islamic Azad University, Damghan Branch, Iran
  • Tabarraei, A, Infectious Diseases Research Centre, Golestan University of Medical Sciences, Gorgan, Iran
  • Vakili, MA, Infectious Diseases Research Centre, Golestan University of Medical Sciences, Gorgan, Iran
  • Zhand, S, Golestan University of Medical Sciences, Gorgan, Iran
Abstract:

Abstract Background and Objective: Lamivudine is the first orally available drug approved for treatment of chronic hepatitis B. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene contribute resistance to lamivudine. This study was aimed to determine the rate of YMDD and FLLAQ mutants in hepatitis B patients in Golestan Province, Iran. Material and methods: In this cross sectional study, 120 patients with chronic HBV infection were recruited. Of them, 55 were treated and 65 untreated with Lamivudine. HBV DNA extractions from plasma and polymerase chain reaction (PCR) were performed. For detection of Lamivudine mutants direct sequencing and alignment of products were applied using reference sequence from Gene Bank database. Results: the average age of patients was 36.31±10.07, which 35% of them were female and 65% were male. Mutations at the YMDD and FLLAQ motifs in the domains of HBV polymerase gene were detected in 12 of 55 patients (21.81%) treated with Lamivudine while no mutation was observed in in untreated patients. The YMDD and FLLAQ mutants were detected in 9.16% (11/120) and 0.83% (1/120) of chronic HBV patients, respectively. Conclusion: Usual HBV mutations, which play an important role in lamivudine resistance, detected in this study are similar to other studies. Key words: Hepatitis B Viruse, YMDD Mutation, Lamivudine, Iran.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Frequency of YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines

 Abstract Background: Investigators were suspicious of tyrosine-methionine-aspartate-aspartate (YMDD) mutations occurred only in patients who were treated by lamivudine. However, YMDD mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines was reported in some studies. The aim of this study was to evaluate YMDD mutations in Ira...

full text

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Objective (s):The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. Materials and Methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples...

full text

YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.

AIM To polymerase P region (YMDD) mutations of hepatitis B virus gene (HBV DNA) in patients with chronic hepatitis B (CHB) untreated with antiviral medicines and to explore its correlation with pre-c-zone mutations, HBV genotypes and HBV DNA level, and to observe its curative effect. METHODS A total of 104 cases (38 cases in group of familial aggregation and 66 cases in group of non-familial ...

full text

Mutations at Nucleotide 1762, 1764 and 1766 of Hepatitis B Virus X Gene in Patients with Chronic Hepatitis B and Hepatitis B-Related Cirrhosis

Abstract       Background and objective: Hepatitis B virus (HBV) is a DNA virus with high tendency toward hepatic tissue. There are currently about 3 million HBV-infected people and 350 to 400 million chronic carriers of this virus in the world. X protein plays a role in the over-expression of oncogenes, carcinogenicity of liver cells and overlaps with the basal co...

full text

frequency of ymdd mutations in patients with chronic hepatitis b untreated with antiviral medicines

abstract background: investigators were suspicious of tyrosine-methionine-aspartate-aspartate (ymdd) mutations occurred only in patients who were treated by lamivudine. however, ymdd mutations of hepatitis b virus gene (hbv dna) in patients with chronic hepatitis b (chb) untreated with antiviral medicines was reported in some studies. the aim of this study was to evaluate ymdd mutations in iran...

full text

Compensatory variances of drug-induced hepatitis B virus YMDD mutations

Although the drug-induced mutations of HBV have been ever documented, the evolutionary mechanism is still obscure. To deeply reveal molecular characters of HBV evolution under the special condition, here we made a comprehensive investigation of the molecular variation of the 3432 wild-type sequences and 439 YMDD variants from HBV genotype A, B, C and D, and evaluated the co-variant patterns and...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 8  issue 5

pages  7- 13

publication date 2015-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023